Describe the effects of SGLT2 inhibitors on prevention and treatment of heart failure and kidney disease. |
|
|
|
|
|
Describe the effects of GLP1 receptor agonists on major adverse cardiovascular events in patients with type 2 diabetes. |
|
|
|
|
|
Utilize the current guideline recommendations for SGLT2 inhibitors and GLP1 receptor agonists from diabetes, cardiovascular and kidney professional societies. |
|
|
|
|
|